Cencora (NYSE:COR) Releases Earnings Results, Beats Estimates By $0.05 EPS

Cencora (NYSE:COR) announced its earnings results on Wednesday. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05, Zacks reports. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the firm earned $3.34 EPS. Cencora’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora updated its FY 2026 guidance to 17.450-17.75 EPS.

Cencora Price Performance

Cencora stock traded up $6.29 during trading hours on Thursday, hitting $360.29. 1,954,555 shares of the company traded hands, compared to its average volume of 1,541,125. The firm’s 50-day simple moving average is $311.49 and its two-hundred day simple moving average is $298.36. The firm has a market cap of $69.85 billion, a P/E ratio of 37.07, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora has a 1-year low of $223.92 and a 1-year high of $362.00.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 22.63%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently added to or reduced their stakes in COR. MUFG Securities EMEA plc bought a new position in shares of Cencora during the 2nd quarter worth approximately $152,000. ICONIQ Capital LLC bought a new stake in shares of Cencora during the second quarter worth about $207,000. Ausdal Financial Partners Inc. bought a new stake in Cencora in the second quarter valued at approximately $221,000. State of Wyoming raised its position in shares of Cencora by 44.2% during the second quarter. State of Wyoming now owns 1,070 shares of the company’s stock worth $321,000 after purchasing an additional 328 shares during the period. Finally, Modern Wealth Management LLC raised its position in Cencora by 7.6% in the 2nd quarter. Modern Wealth Management LLC now owns 1,118 shares of the company’s stock valued at $335,000 after buying an additional 79 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on COR. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Robert W. Baird boosted their price target on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday. Finally, Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $342.73.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.